Obesity, immunomodulation and chronic kidney disease

Emma Börgeson, Kumar Sharma

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Obesity-induced inflammation is associated with numerous pathologies and is an independent risk factor of chronic kidney disease (CKD). The prevalence of CKD is escalating and current therapeutic strategies are seriously lacking in efficacy, and immunomodulation has been suggested as a potential new therapeutic approach. Indeed, specialized pro-resolving mediators (SPMs), such as lipoxins (LXs), resolvins and protectins, have demonstrated protection in adipose inflammation, restoring insulin sensitivity and adiponectin production, while modulating leukocyte infiltration and promoting resolution in visceral adipose tissue. Furthermore, SPMs display direct renoprotective effect. Thus we review current evidence of immunomodulation as a potential strategy to subvert obesity-related CKD.

Original languageEnglish (US)
Pages (from-to)618-624
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume13
Issue number4
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Immunomodulation
Chronic Renal Insufficiency
Obesity
CD59 Antigens
Lipoxins
Inflammation
Intra-Abdominal Fat
Adiponectin
Insulin Resistance
Leukocytes
Pathology
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Obesity, immunomodulation and chronic kidney disease. / Börgeson, Emma; Sharma, Kumar.

In: Current Opinion in Pharmacology, Vol. 13, No. 4, 01.01.2013, p. 618-624.

Research output: Contribution to journalArticle

@article{3b440569da814a3caaf20684b503a62a,
title = "Obesity, immunomodulation and chronic kidney disease",
abstract = "Obesity-induced inflammation is associated with numerous pathologies and is an independent risk factor of chronic kidney disease (CKD). The prevalence of CKD is escalating and current therapeutic strategies are seriously lacking in efficacy, and immunomodulation has been suggested as a potential new therapeutic approach. Indeed, specialized pro-resolving mediators (SPMs), such as lipoxins (LXs), resolvins and protectins, have demonstrated protection in adipose inflammation, restoring insulin sensitivity and adiponectin production, while modulating leukocyte infiltration and promoting resolution in visceral adipose tissue. Furthermore, SPMs display direct renoprotective effect. Thus we review current evidence of immunomodulation as a potential strategy to subvert obesity-related CKD.",
author = "Emma B{\"o}rgeson and Kumar Sharma",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.coph.2013.05.011",
language = "English (US)",
volume = "13",
pages = "618--624",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Obesity, immunomodulation and chronic kidney disease

AU - Börgeson, Emma

AU - Sharma, Kumar

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Obesity-induced inflammation is associated with numerous pathologies and is an independent risk factor of chronic kidney disease (CKD). The prevalence of CKD is escalating and current therapeutic strategies are seriously lacking in efficacy, and immunomodulation has been suggested as a potential new therapeutic approach. Indeed, specialized pro-resolving mediators (SPMs), such as lipoxins (LXs), resolvins and protectins, have demonstrated protection in adipose inflammation, restoring insulin sensitivity and adiponectin production, while modulating leukocyte infiltration and promoting resolution in visceral adipose tissue. Furthermore, SPMs display direct renoprotective effect. Thus we review current evidence of immunomodulation as a potential strategy to subvert obesity-related CKD.

AB - Obesity-induced inflammation is associated with numerous pathologies and is an independent risk factor of chronic kidney disease (CKD). The prevalence of CKD is escalating and current therapeutic strategies are seriously lacking in efficacy, and immunomodulation has been suggested as a potential new therapeutic approach. Indeed, specialized pro-resolving mediators (SPMs), such as lipoxins (LXs), resolvins and protectins, have demonstrated protection in adipose inflammation, restoring insulin sensitivity and adiponectin production, while modulating leukocyte infiltration and promoting resolution in visceral adipose tissue. Furthermore, SPMs display direct renoprotective effect. Thus we review current evidence of immunomodulation as a potential strategy to subvert obesity-related CKD.

UR - http://www.scopus.com/inward/record.url?scp=84885956835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885956835&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2013.05.011

DO - 10.1016/j.coph.2013.05.011

M3 - Article

VL - 13

SP - 618

EP - 624

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 4

ER -